secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001193125-23-196808
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen to acquire Reata for $172.50/share, ~$7.3B enterprise value
------------------------------------------------------------------

- Deal price $172.50/share in cash; total enterprise value ~$7.3 billion.
- Expected closing in Q4 2023; subject to Reata stockholder approval and regulatory clearances.
- Biogen to finance with cash on hand plus term debt; voting agreements cover ~36% of Reata shares.
- Acquisition expected to be slightly dilutive to Biogen non-GAAP EPS in 2023, neutral in 2024, significantly accretive from 2025.
- Reata's SKYCLARYS is the first FDA-approved treatment for Friedreich's ataxia; launch underway, EU review ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312523196808/0001193125-23-196808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312523196808/d507671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-196808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer